Study ID | Subject | Mean age of Saffron group (year) | Mean age of control group (year) | Sample size, gender (F/M) | Study design | Form of saffron | Dosage (mg/day) | Control, mg/day | Duration (wk) | Outcome Measurement |
---|---|---|---|---|---|---|---|---|---|---|
Akhondzadeh 2010 [16] | AD | 72.70 ± 6.20 | 73.85 ± 4.63 | 54 (25/29) | multicentre, double blind RCT | extract | 30 | donepezil, 10 | 22 | ADAS-cog, CDR-SB, safety |
Akhondzadeh 2010 [17] | AD | 72.65 ± 3.89 | 73.13 ± 4.70 | 46 (21/25) | double blind RCT | extract | 30 | placebo | 16 | ADAS-cog, CDR-SB, safety |
Farokhnia 2014 [18] | moderate to severe AD | 77.73 ± 8.05 | 77.47 ± 7.99 | 68 (29/39) | double blind RCT | extract | 30 | memantine, 20 | 48 | SCIRS, FAST, MMSE, safety |
Tsolaki 2016 [19] | MCI | 71.47 ± 6.73 | 69.72 ± 7.33 | 35 (26/9) | single blind, parallel RCT | powder | 125 | no treatment | 48 | MMSE, FRSSD, MoCA, NPI, GDS, MRI, EEG |